MAIA Biotechnology, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $70.4M
- Price
- $1.14
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.39%
- Volume
- 215.4K
About
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Quick stats
Shares outstanding61.7M
Computed float52.8M
Float / shares85.5%
Cash runway (months)9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001878313
Websitehttps://www.MAIABiotech.com
AI Summary
AI-generated1/24
minorbullishclinical trial
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
MAIA Biotechnology reached enrollment milestones across its ateganosine NSCLC trials, with 150 patients treated and Part C of the Phase 2 THIO-101 trial fully enrolled.
The pivotal Phase 3 THIO-104 trial has 65 patients enrolled, tracking toward its target of 100 by year-end 2026 with an interim analysis planned in 2027.
The Phase 2 combination with cemiplimab showed a 90.5% interim disease control rate, close to triple standard-of-care chemotherapy outcomes; ateganosine holds FDA Fast Track designation.